Latest Neuraminidase inhibitors Stories
SAN DIEGO, July 26 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the U.S.
Fraudulent product is dangerous to patients allergic to penicillin.
Fraudulent product is dangerous to patients allergic to penicillin SILVER SPRING, Md., June 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.
Scientists from Hong Kong and Canada have identified a chemical compound that can halt the replication of both the H5N1 bird flu virus and the seasonal human flu virus.
EMERYVILLE, Calif., April 28 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients.
Tamiflu and two other drugs used to treat influenza appear safe for pregnant women and their babies, researchers at UT Southwestern Medical Center have found in a retrospective study of 239 cases of women who received the medications during pregnancy.
ST. PAUL, Minn., March 31 /PRNewswire/ -- Prime Therapeutics LLC (Prime), a thought leader in pharmacy benefit management, will present five new studies at the Academy of Managed Care Pharmacy's (AMCP) annual meeting, April 7-10, 2010 in San Diego.
Doctors reported on Friday that the H1N1 swine flu virus can develop resistance to antivirus treatments very quickly.
EMERYVILLE, Calif., March 15 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses.
- Growing in low tufty patches.
More Images (1 images) »